Cerebrospinal fluid biomarkers of neurodegeneration in patients with juvenile and classic myotonic dystrophy type 1

被引:23
|
作者
Peric, S. [1 ]
Mandic-Stojmenovic, G. [1 ]
Markovic, I. [2 ]
Stefanova, E. [1 ,3 ]
Ilic, V. [1 ]
Parojcic, A. [1 ]
Misirlic-Dencic, S. [2 ]
Ostojic, M. [4 ]
Rakocevic-Stojanovic, V. [1 ,3 ]
Kostic, V. [1 ,3 ]
机构
[1] Univ Belgrade, Neurol Clin, Clin Ctr Serbia, Belgrade 11000, Serbia
[2] Univ Belgrade, Sch Med, Inst Med & Clin Biochem, Belgrade 11000, Serbia
[3] Univ Belgrade, Sch Med, Belgrade 11000, Serbia
[4] Inst Orthoped Surg & Traumatol, Belgrade, Serbia
关键词
amyloid beta protein; cerebrospinal fluid; myotonic dystrophy type 1; tau protein; ALZHEIMERS-DISEASE; RATING-SCALE; TAU; BRAIN; DYSREGULATION; IMPAIRMENT; DEPRESSION; SCLEROSIS; PROTEINS; FATIGUE;
D O I
10.1111/ene.12237
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and purposeThe aim of the present study was to analyze cerebrospinal fluid (CSF) levels of total tau (T-tau), phosphorylated tau (P-tau) and the 42-amino-acid form of -amyloid (A(42)) in patients with myotonic dystrophy type 1 (DM1), and their possible correlations with cognitive and behavioral manifestations in these patients. MethodsLumbar puncture was performed in 74 patients with DM1 [27 with the childhood/juvenile form (jDM1) and 47 with the adult form (aDM1) of the disease] and 26 control subjects who were subjected to orthopedic surgery. Sandwich ELISA was used for measuring the levels of T-tau, P-tau and A(42). ResultsThe CSF level of A(42) was at its lowest in patients with jDM1 and at its highest in controls (P<0.05). A tendency of T-tau and P-tau to increase was greater in aDM1 patients than in jDM1 patients and controls (P>0.05). In both jDM1 and aDM1 patients, significant correlations were found between A(42) and T-tau (rho=0.81 and rho=0.67, respectively, P<0.01), as well as between A(42) and P-tau (rho=0.87 and rho=0.67, respectively, P<0.01). The A(42)/P-tau ratio decreased with age in aDM1 patients (rho=-0.30, P<0.05). Only the level of A(42) in the CSF of jDM1 patients was correlated with the size of the CTG expansion (rho=-0.53, P<0.05). Only a few correlations were observed between levels of biomarkers and neuropsychological testing. ConclusionThe CSF level of A(42) was decreased in patients with jDM1, whilst the A(42)/P-tau ratio was decreased in aDM1 patients. Positive correlations between A(42), T-tau and P-tau were observed in both forms of disease. Further studies with larger cohorts of DM1 patients are necessary. Click here to view the accompanying paper in this issue.
引用
收藏
页码:231 / 237
页数:7
相关论文
共 50 条
  • [1] Extracellular RNA splice events in cerebrospinal fluid as candidate biomarkers of myotonic dystrophy type 1
    Kumari, Preeti
    Hu, Ningyan
    Sizemore, Alex
    Sullivan, Lauren
    Mckee, Brigham
    Conquest, Parker
    Wheeler, Thurman
    NEUROLOGY, 2023, 100 (17)
  • [2] Cerebrospinal fluid biomarkers of neurodegeneration in narcolepsy type 1
    Baiardi, Simone
    Pizza, Fabio
    Polischi, Barbara
    Moresco, Monica
    Abu-Rumeileh, Samir
    Plazzi, Giuseppe
    Parchi, Piero
    SLEEP, 2020, 43 (02)
  • [3] Tau positron emission tomography, cerebrospinal fluid and plasma biomarkers of neurodegeneration, and neurocognitive testing: an exploratory study of participants with myotonic dystrophy type 1
    Robert Jr Laforce
    Caroline Dallaire-Théroux
    Annie M. Racine
    Gersham Dent
    Cristian Salinas-Valenzuela
    Elizabeth Poulin
    Anne-Marie Cayer
    Daphnée Bédard-Tremblay
    Thierry Rouleau-Bonenfant
    Frédéric St-Onge
    Susanna Schraen-Maschke
    Jean-Mathieu Beauregard
    Nicolas Sergeant
    Jack Puymirat
    Journal of Neurology, 2022, 269 : 3579 - 3587
  • [4] Tau positron emission tomography, cerebrospinal fluid and plasma biomarkers of neurodegeneration, and neurocognitive testing: an exploratory study of participants with myotonic dystrophy type 1
    Laforce, Robert Jr Jr
    Dallaire-Theroux, Caroline
    Racine, Annie M.
    Dent, Gersham
    Salinas-Valenzuela, Cristian
    Poulin, Elizabeth
    Cayer, Anne-Marie
    Bedard-Tremblay, Daphnee
    Rouleau-Bonenfant, Thierry
    St-Onge, Frederic
    Schraen-Maschke, Susanna
    Beauregard, Jean-Mathieu
    Sergeant, Nicolas
    Puymirat, Jack
    JOURNAL OF NEUROLOGY, 2022, 269 (07) : 3579 - 3587
  • [5] Cerebrospinal fluid tau and amyloid β42 protein in patients with myotonic dystrophy type 1
    Winblad, S.
    Mansson, J. E.
    Blennow, K.
    Jensen, C.
    Samuelsson, L.
    Lindberg, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 (09) : 947 - 952
  • [6] Multisystemic manifestations in adult patients with classic myotonic dystrophy type 1
    Iterbeke, L.
    Claeys, K.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [7] Molecular biomarkers in myotonic dystrophy type 1
    Slipsager, A.
    Hildonen, M.
    Stemmerik, M. Godtfeldt
    Tumer, Z.
    Duno, M.
    Birkedal, U.
    Vissing, J.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S155 - S155
  • [8] Molecular biomarkers in myotonic dystrophy type 1
    Slipsager, A.
    Hildonen, M.
    Stemmerik, M. Godtfeldt
    Tumer, Z.
    Duno, M.
    Birkedal, U.
    Vissing, J.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [9] Orexin/hypocretin levels in the cerebrospinal fluid and characteristics of patients with myotonic dystrophy type 1 with excessive daytime sleepiness
    Omori, Yuki
    Kanbayashi, Takashi
    Imanishi, Aya
    Tsutsui, Ko
    Sagawa, Yohei
    Kikuchi, Yuka S.
    Takeshima, Masahiro
    Yoshizawa, Kazuhisa
    Uemura, Sachiko
    Shimizu, Tetsuo
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2018, 14 : 451 - 457
  • [10] Plasma microRNAs as biomarkers for myotonic dystrophy type 1
    Perfetti, Alessandra
    Greco, Simona
    Bugiardini, Enrico
    Cardani, Rosanna
    Gaia, Paola
    Gaetano, Carlo
    Meola, Giovanni
    Martelli, Fabio
    NEUROMUSCULAR DISORDERS, 2014, 24 (06) : 509 - 515